Literature DB >> 19125845

Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report.

Gaetano Gorgone1, Daniela Caccamo, Laura Rosa Pisani, Monica Currò, Giulia Parisi, Giancarla Oteri, Riccardo Ientile, Paolo Maria Rossini, Francesco Pisani.   

Abstract

PURPOSE: Brain atrophy (BA) is observed in 20-50% of patients with epilepsy. Hyper-total-homocysteinemia (hyper-tHcy), which occurs in 10-40% of patients, is considered to be a risk factor for cardiovascular diseases and BA. The present study was aimed at investigating the possible association of hyper-tHcy with BA in a population of patients with epilepsy.
METHODS: Fifty-eight patients (33 M/25 F, 43.5 +/- 13.1 years of age) chronically treated with antiepileptic drugs (AEDs) and 60 controls matched for age and sex were enrolled. All participants underwent determination of plasma tHcy, folate, vitamin B(12), and C677T methylene-tetrahydrofolate-reductase (MTHFR) polymorphism genotyping, and brain magnetic resonance imaging (MRI).
RESULTS: Patients exhibited significantly higher tHcy and lower folate levels than controls; hyper-tHcy was significantly associated with the variables group (patients vs. controls), MTHFR genotype, and their interaction terms. BA was observed in 30.1% of patients and was significantly associated with hyper-tHcy (beta = 0.45, p = 0.003) and polytherapy (beta = 0.31, p < 0.001). DISCUSSION: Our investigation suggests that hyper-tHcy plays a role in the development of BA in patients with epilepsy. Although the real origin of this phenomenon is not yet fully elucidated, experimental data support the hypothesis of a link of the neuronal Hcy-mediated damage with oxidative stress and excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125845     DOI: 10.1111/j.1528-1167.2008.01967.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

1.  The 894G > T (Glu298Asp) variant in the endothelial NOS gene and MTHFR polymorphisms influence homocysteine levels in patients with cognitive decline.

Authors:  Nadia Ferlazzo; Gaetano Gorgone; Daniela Caccamo; Monica Currò; Salvatore Condello; Francesco Pisani; Fabrizio Vernieri; Paolo Maria Rossini; Riccardo Ientile
Journal:  Neuromolecular Med       Date:  2011-05-24       Impact factor: 3.843

2.  Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epilepsy.

Authors:  Vandana Rai; Pradeep Kumar
Journal:  Neurol Sci       Date:  2018-09-28       Impact factor: 3.307

3.  Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment.

Authors:  Enrica Baldelli; Giuseppina Leo; Nicola Andreoli; Kjell Fuxe; Giuseppe Biagini; Luigi F Agnati
Journal:  Neuromolecular Med       Date:  2009-12-22       Impact factor: 3.843

Review 4.  Hyperhomocysteinemia and neurologic disorders: a review.

Authors:  Ramin Ansari; Ali Mahta; Eric Mallack; Jin Jun Luo
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

5.  Short-Term and Long-Term Effects of Levetiracetam Monotherapy on Homocysteine Metabolism in Children with Epilepsy: A Prospective Study.

Authors:  Achilleas Attilakos; Maria Paschalidou; Anastasia Garoufi; Maria Tsirouda; Anna Papadopoulou; Maria Karalexi; Argirios Dinopoulos
Journal:  J Clin Neurol       Date:  2019-04       Impact factor: 3.077

6.  Effects of phenytoin on serum levels of homocysteine, vitamin B12, folate in patients with epilepsy: A systematic review and meta-analysis (PRISMA-compliant article).

Authors:  Yubin Xu; Na Zhang; Shanshan Xu; Hongyan Xu; Saizhen Chen; Zhelin Xia
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 7.  Involvements of Hyperhomocysteinemia in Neurological Disorders.

Authors:  Marika Cordaro; Rosalba Siracusa; Roberta Fusco; Salvatore Cuzzocrea; Rosanna Di Paola; Daniela Impellizzeri
Journal:  Metabolites       Date:  2021-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.